Cover Image
市場調查報告書

低性促素的性腺功能低下症:開發平台分析

Hypogonadotropic Hypogonadism - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 288830
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
低性促素的性腺功能低下症:開發平台分析 Hypogonadotropic Hypogonadism - Pipeline Review, H2 2015
出版日期: 2015年09月09日 內容資訊: 英文 62 Pages
簡介

所謂低性促素的性腺功能低下症(HH)是由於腦垂體或視丘下部的異常造成性腺功能降低症的一種,症狀有嗅覺障礙,青春期的發育不足,女性則有乳房發育不足,無月經等。由於遺傳性缺陷和損傷造成的障礙,感染,腫瘤,手術對腦垂體或視丘下部的影響,類固醇或類鴉片物質的長期使用等是致病原因。

本報告涵括全球低性促素的性腺功能低下症治療藥之開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及他們開發中的產品檢討等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

低性促素的性腺功能低下症概要

治療藥的開發

  • 低性促素的性腺功能低下症開發中產品:概要
  • 低性促素的性腺功能低下症開發中產品:比較分析

低性促素的性腺功能低下症:開發中的治療藥:各企業

低性促素的性腺功能低下症:開發中的治療藥:大學·研究機關別

低性促素的性腺功能低下症:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

低性促素的性腺功能低下症:開發中的產品:各企業

低性促素的性腺功能低下症:開發中的產品:大學·研究機關別

低性促素的性腺功能低下症:治療藥的開發企業

  • BIOCAD
  • Forendo Pharma Oy
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • Repros Therapeutics Inc.

低性促素的性腺功能低下症:治療藥的評估

  • 單劑治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BGS-649
    • 產品概要
    • 作用機制
    • R&D的進展
  • corifollitropin alfa
  • enclomiphene
  • fispemifene
  • follitropin alfa
  • Kisspeptin-10
  • TAK-448
  • testosterone undecanoate

最新的開發平台趨勢

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7160IDB

Summary

Global Markets Direct's, 'Hypogonadotropic Hypogonadism - Pipeline Review, H2 2015', provides an overview of the Hypogonadotropic Hypogonadism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypogonadotropic Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypogonadotropic Hypogonadism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hypogonadotropic Hypogonadism
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hypogonadotropic Hypogonadism and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hypogonadotropic Hypogonadism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hypogonadotropic Hypogonadism pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hypogonadotropic Hypogonadism
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hypogonadotropic Hypogonadism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hypogonadotropic Hypogonadism Overview
  • Therapeutics Development
    • Pipeline Products for Hypogonadotropic Hypogonadism - Overview
    • Pipeline Products for Hypogonadotropic Hypogonadism - Comparative Analysis
  • Hypogonadotropic Hypogonadism - Therapeutics under Development by Companies
  • Hypogonadotropic Hypogonadism - Therapeutics under Investigation by Universities/Institutes
  • Hypogonadotropic Hypogonadism - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hypogonadotropic Hypogonadism - Products under Development by Companies
  • Hypogonadotropic Hypogonadism - Products under Investigation by Universities/Institutes
  • Hypogonadotropic Hypogonadism - Companies Involved in Therapeutics Development
    • BIOCAD
    • Forendo Pharma Oy
    • Merck & Co., Inc.
    • Millennium Pharmaceuticals, Inc.
    • Repros Therapeutics Inc.
  • Hypogonadotropic Hypogonadism - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BGS-649 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • corifollitropin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • enclomiphene - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fispemifene - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • follitropin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Kisspeptin-10 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAK-448 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • testosterone undecanoate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hypogonadotropic Hypogonadism - Recent Pipeline Updates
  • Hypogonadotropic Hypogonadism - Product Development Milestones
    • Featured News & Press Releases
      • Jun 08, 2015: Repros Announces Date of FDA Advisory Committee Review of NDA
      • Apr 15, 2015: Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application
      • Apr 06, 2015: Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization Application to the European Medicines Agency as a New Active Substance
      • Apr 01, 2015: Repros Announces Acceptance for Filing of NDA
      • Oct 27, 2014: Repros to Webcast Investor and Analyst Day on October 31st
      • Oct 21, 2014: Results From Long-Term Study of Androxal Exhibit Positive Safety Profile
      • Sep 26, 2014: FDA Schedules Type B Pre-NDA Meeting With Repros
      • Sep 25, 2014: Androxal Second Pivotal Study Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints Versus Marketed Topical Gel in the Treatment of Secondary Hypogonadism
      • Jul 16, 2014: FDA Confirms Sperm and Testosterone Endpoints as Key Parameters for Assessment of Androxal Versus Approved Topical Gel and Placebo
      • May 13, 2014: Repros Fully Enrolls Second Previously Announced Head to Head Study of Androxal(R) Versus the Leading Topical Testosterone Gel
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hypogonadotropic Hypogonadism, H2 2015
  • Number of Products under Development for Hypogonadotropic Hypogonadism - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Hypogonadotropic Hypogonadism - Pipeline by BIOCAD, H2 2015
  • Hypogonadotropic Hypogonadism - Pipeline by Forendo Pharma Oy, H2 2015
  • Hypogonadotropic Hypogonadism - Pipeline by Merck & Co., Inc., H2 2015
  • Hypogonadotropic Hypogonadism - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
  • Hypogonadotropic Hypogonadism - Pipeline by Repros Therapeutics Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Hypogonadotropic Hypogonadism Therapeutics - Recent Pipeline Updates, H2 2015

List of Figures

  • Number of Products under Development for Hypogonadotropic Hypogonadism, H2 2015
  • Number of Products under Development for Hypogonadotropic Hypogonadism - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top